We asked HIV community leaders how their priorities have changed since Trump’s election – and what they see as the most important challenges to the fight against HIV under a Trump presidency.
Among our featured reports this week, we learn about how the vaginal microbiome may affect antiretroviral concentrations in the genital tract, and we look at the potential impact of global supply-chain interruptions on HIV drug resistance.
Among our four featured reports this week, we learn about the critical intersection between HIV treatment access and reduced HIV incidence in the U.S. -- and about the value of replacing placebos with PrEP in clinical trials on HIV prevention.
Among the research we review this week, we highlight data showing just how far the U.S. still has to go in keeping HIV-positive people within some high-risk communities connected to care after they're diagnosed.
We look at peroxisomes and neurocognitive impairment; injectable cabotegravir for PrEP; genital bacteria and HIV risk; and how HIV diagnosis relates to intimate partner violence among pregnant women.
The HIV community has reacted with shock and sadness to news that Mark Wainberg, Ph.D., died on April 12.
Long-acting antiretrovirals: Are they the future of HIV treatment or will the future pass them by? Researcher Charles W. Flexner recently addressed several common myths.
Women with HIV tend to perform worse than HIV-negative women on cognitive performance tests, even after many years on treatment, new research finds -- but trends differed depending on the test and on women's treatment success.
Paul Sax, M.D., discusses the clinical importance of new drugs in development highlighted at CROI 2017 -- and about what else is on the near horizon when it comes to antiretroviral therapies for HIV.